Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14
06 April 2022 - 2:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company
advancing new treatments for patients suffering from serious
diseases underserved by current therapies, today announced that
Jonathan Violin, Ph.D., President and Chief Executive Officer will
participate in the 21st Annual Needham Virtual Healthcare
Conference on Thursday, April 14, 2022, which includes a
presentation beginning at 4:30 p.m. ET.
21st
Annual Needham Virtual Healthcare
Conference |
Format: |
Corporate
Overview |
Date: |
Thursday, April 14, 2022 |
Time: |
4:30 p.m. ET |
Webcast Link |
The live webcast and a replay of the presentation can be
accessed under “Events” in the Investors section of the Viridian
Therapeutics, Inc. website.
About Viridian TherapeuticsViridian
Therapeutics is a biotechnology company advancing new treatments
for patients suffering from serious diseases but underserved by
today’s therapies. Viridian’s most advanced program, VRDN-001, is a
differentiated humanized monoclonal antibody targeting insulin-like
growth factor-1 receptor (IGF-1R), a clinically and commercially
validated target for the treatment of thyroid eye disease (TED).
Viridian’s second product candidate, VRDN-002, is a distinct
anti-IGF-1R antibody that incorporates half-life extension
technology and is designed to support administration as a
convenient, low-volume, subcutaneous injection. TED is a
debilitating autoimmune disease that causes inflammation and
fibrosis within the orbit of the eye which can cause double vision,
pain, and potential blindness. Patients with severe disease often
require multiple remedial surgeries to the orbit, eye muscles and
eyelids. Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:John JordanViridian
TherapeuticsVice President, Investor Relations& Corporate
Communications617-272-4691IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Okt 2023 bis Okt 2024